Introduction
Sesamin is a major lignan in sesame, and its biological effects such as antioxidant effect (Ikeda et al., 2003; Nakai et al., 2003) , anticarcinogenic effects (Hirose et al., 1992; Miyahara et al., 2000) , and suppresion of hypertension (Miyawaki et al., 2009) have been extensively studied by many researchers. Thus, sesamin appears to be one of the most reliable food factors whose effects can be expected by individuals taking it as a supplement or remedy. Meanwhile, some food factors are known to affect the xenobiotic metabolism. For example, some flavonoids show potent inhibitions of CYPs, and interfere with the metabolism of therapeutic drugs. (Cermak and Wolffram, 2006) .
Furthermore, there have been some reports of mechanism-based inhibition (MBI) of
CYPs by methylenedioxyphenyl (MDP) compounds (Nakajima et al., 1999; Murray, 2000; Chatterjee and Franklin, 2003; Usia et al., 2005) . Usia et al. (2005) demonstrated that some lignans which contain MDP group have potent MBI of CYP3A4. As sesamin has two MDP groups, it might cause MBI of some CYPs. However, no reports on MBI of CYPs by sesamin have been published to our best knowledge. Thus, in this study, we examined whether sesamin could cause MBI or not. Nakai et al. (2003) demonstrated that sesamin was metabolized to mono-and di-catechol metabolites in rat liver. They assumed that some CYPs were involved in sesamin catecholization, since MDP compounds were demethylated by CYP-dependent oxidation (Kumagai et al., 1991; Murray, 2000) . Sesamin was also converted to some metabolites including mono-and di-catechol metabolites by in vitro fermentation of human feces or in vivo administration (Penalvo et al., 2005; Liu et al., 2006) . Moreover, mono-catechol compound was also detected as a human urinary sesamin metabolite (Moazzami et al., 2007) . Liu et al. (2006) proposed tentative metabolic pathways of sesamin. Among the 11 kinds of the metabolites, mono-and di-catechol metabolites, D M D # 3 5 6 5 9 5 which appear to be metabolized by CYPs, are known to have high antioxidative activities (Nakai et al., 2003; Miyake et al., 2005) . It was reported that sesamin elevated CYP2B and CYP4A mRNA levels in rats (Tsuruoka et al., 2005; Ikeda et al., 2007) , and CYP1A activity in rainbow trouts (Trattner et al., 2008) . In addition, sesamin inhibited CYP4F2 to elevate tocopherol levels (Sontag and Parker, 2002) . However, to the best of our knowledge, there is no report to identify CYP isoforms responsible for sesamin metabolism in humans or to estimate the drug-sesamin interaction.
To predict drug metabolism in human body, we established yeast expression system for human CYPs, and showed its usefulness for the prediction of drugs or environmental contaminants (Imaoka et al., 1996; Hayashi et al., 2000; Sakaki and Inouye, 2000; Inouye et al., 2002) . In this study, the yeast expression system and human liver microsomes were used to identify a CYP isoform responsible for the metabolism of sesamin in human body. In addition, we describe the mechanism-based inhibition of CYP2C9 by sesamin.
Materials and methods

Materials.
Sesamin, sulfaphenazole, and (+)-N-3-benzylnirvanol were purchased from Sigma-Aldrich (St. Louis, MO). NADPH was purchased from Oriental Yeast Co., Ltd.
(Tokyo, Japan). Human single donor liver microsomes (HG43, HH47, HH18, HH74, HH77, HG95, HH715, HH581, HG3, and HH741) and a 50 donor human liver microsome pool were purchased from BD Gentest (Woburn, MA , and a glyceraldehydes-3-phosphate dehydrogenase (GAPDH) promoter and terminator derived from zygosaccharomyces rouxii. The microsomes prepared from the recombinant S. cerevisiae cells expressing human CYPs were purchased from Sumika Chemical Analysis Service (Osaka, Japan).
Sesamin mono-catechol and di-catechol were obtained by using rat liver microsomes, and used them as authentic standards. All other chemicals were purchased from standard commercial sources of the highest quality available. 
Metabolism of Sesamin by
Inhibition of Sesamin Catecholization in Human Liver Microsomes by CYP Isoform -specific Inhibitors
The reaction mixture (100 μ l) containing 0.5 mg protein/ml of pooled human liver microsomes and 0.1 to 5 μM sulfaphenazole (CYP2C9 specific inhibitor) or (+)-N-3-benzylnirvanol (CYP2C19 specific inhibitor) in 100 mM potassium phosphate buffer (pH 7.4) were pre-incubated at 37°C for 5 min. After the pre-incubation, 5 μ M sesamin and 1 mM NADPH were added, and incubation was continued for 15 min. The metabolite was analyzed as described above. Inhibition of the CYP isoform-specific Activity by Sesamin.
The reaction mixture containing 0.5 mg protein/ml of recombinant yeast microsomes containing each of CYP1A2, 2C9, and 3A4, 1 mM NADPH, and various concentrations of sesamin (0-50 μM) and phenacetin (5-50 μM) for CYP1A2 or diclofenac (5-50 μM) for CYP2C9 or testosterone (5-100 μM) for CYP3A4 in 100 mM potassium phosphate buffer (pH 7.4) was incubated at 37°C for 15 min. Their metabolites were analyzed as described above for sesamin, phenacetin, and diclofenac.
For testosterone, the same methods used for sesamin were used except for the HPLC conditions; UV detection, 290 nm; liner gradients of 20-100% acetonitrile aqueous solution per 25 min. The types of inhibition were determined from Lineweaver-Burk plots, and the inhibitor constants (K i ) were calculated from the Dixon plot (Dixon, 1953) .
Mechanism-based Inhibition of CYP.
The reaction mixture containing 0.5 mg protein/ml of recombinant yeast microsomes or 50 donor human liver microsome pool, 1mM NADPH and various concentrations of sesamin (0-50 μM) in 100 mM potassium phosphate buffer (pH 7.4)
1 0 was pre-incubated at 37°C for 0, 5, and 10 min. After the pre-incubation, substrates for each CYP-specific activity were added at the final concentration of 100 μM and incubation was continued for 15 min under the same conditions. Their metabolites were analyzed as described above. Kinetic parameters of inactivation process were calculated according to the method of Waley (Waley, 1980; Waley, 1985) . The observed rate constant of inactivation (k obs ) was calculated from the initial slopes of the liner regression line of the 'residual activity' versus 'pre-incubation time' profile plotted on a semilogarithmic scale. The inactivation rate constant at infinite concentration of inhibitor (k inact ) and the appeared inhibitor constants (K i ) were calculated from the double reciprocal plots of k obs versus sesamin concentration.
.
Measurement of CYP Hemoproteins.
The contents of CYP hemoprotein in the recombinant yeast cells were measured as described previously (Oeda et al., 1985) . Yeast cells (100mL culture) were harvested during logarithmic growth phase, washed twice by suspension in 100mM potassium phosphate buffer pH 7.4, and then suspended in 5mL of the buffer. The concentration of CYP hemoprotein in the whole cell fraction or microsomal fraction was determined from the reduced CO-difference spectrum using a difference of the extinction coefficients at 450 and 490 nm of 91 mM -1 cm -1 (Omura and Sato, 1964) .
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Results
Identification of the Metabolite of Seasamin.
Figure 1(A) shows the HPLC profiles of sesamin and its metabolite by the recombinant yeast cells expressing CYP2C19. One major metabolite M1 was observed at a retention time of 25.3 min, and eluted with authentic sesamin mono-catechol with co-chromatography (data not shown). The same metabolite (M1) was detected in microsomes of recombinant yeast cells expressing CYP2C19 (Fig. 1 (B) ). × (the relative content (%) of each CYP in human liver). The relative contents are 1% for CYP2C19, 2 % for CYP2D6, 13 % for CYP1A2, and 20 % for 2C9 (Shimada et al., 1994; Inoue et al., 1997) . Table 2 demonstrates that the putative contribution ratios in human liver are high in the order of CYP2C9, CYP1A2, CYP2C19, and CYP2D6.
Correlation between Sesamin Catecholization Activity and Each CYP-specific Activity in Human Liver Microsomes.
To confirm the prediction that CYP2C9 is essential for the metabolism of sesamin in human liver, we examined the correlation between sesamin catecholization activity and each CYP-specific activity using human single donor liver microsomes. Figure 2 shows sesamin catecholization activity. Activity range was 2.5-fold in sesamin catecholization (Fig 2) , and 6.3-fold in diclofenac 4'-hydroxylation among 10 human liver microsomes, respectively. These data suggest that the inter-individual difference of sesamin
catecholization is not so large. As shown in Fig 3A, good correlation was observed between sesamin catecholization activity and diclofenac 4'-hydroxylation activity, which is known to be a CYP2C9-specific activity (r = 0.94). On the other hand, phenacetin O-deethylation activity, which is known to be CYP1A2-specific reaction,
showed a little correlation (r = 0.33) with sesamin catecholization (Fig 3B) . Both S-mephenytoin 4'-hydroxylation activity, and bufurarol 1'-hydroxylation activity, that are known to be a CYP2C19 and CYP2D6-specific reaction, respectively, showed almost no correlations with sesamin catecholization (data not shown). These results clearly demonstrate that CYP2C9 is a major CYP isoform of sesamin catecholization in human liver. Figure 4 shows the effect of antibodies against human CYPs on sesamin catecholization in the pooled human liver microsomes at different sesamin concentrations, 5 μM (A) or 50 μM (B). At 5 μM of sesamin, catecholization was significantly inhibited by anti-CYP2C9 antibody. In contrast, at 50 μM of sesamin, catecholization was significantly inhibited by not only anti-CYP2C9 antibody but also anti-CYP1A2 antibody, indicating that the contribution of CYP1A2 is larger at 50 μM than that at 5 μM. These results appear to be consistent with the fact that the K m value of CYP1A2 is significantly larger than that of CYP2C9 (Table 2) . At both 5 and 50 μM, 
Inhibition of Sesamin Catecholization in Human Liver Microsomes by Anti-CYP Antibody
Inhibition of Sesamin Catecholization in Human Liver Microsomes by CYP2C9-or
CYP2C19 -specific Inhibitor
To confirm that CYP2C9 is the most essential CYP isoform but CYP2C19 is not, we sulfaphenazole showed a remarkable inhibition of sesamin catecholization activity in pooled human liver microsomes. The K i value was estimated to be 0.24 + 0.03 μM regarding sulfaphenazole as a competitive inhibitor. In contrast, the activity was hardly reduced even in the presence of 5 μM of (+)-N-3-benzylnirvanol. These results strongly suggest that CYP2C9 is the most essential CYP isoform for sesamin monocatecholization in human liver, while the contribution of CYP2C19 is much lower than CYP2C9.
Correlation between Sesamin Catecholization Activity and Each CYP-specific Activity in the Presence of Anti-CYP2C9 Antibody.
To examine a contribution of other CYP isoforms, we further examined the correlation between sesamin catecholization activity and each CYP activity in the presence of anti-CYP2C9. As shown in Fig. 3C sesamin catecholization activity and phenacetin O-deethylation activity, which is known to be CYP1A2-specific reaction, showed a considerable correlation (r = 0.86). However, both S-mephenytoin
1 5 4'-hydroxylation activity and bufurarol 1'-hydroxylation activities showed little correlations with sesamin catecholization activity (data not shown). These results indicate that CYP1A2 is also involved in sesamin catecholization in human liver, though its contribution is smaller than CYP2C9.
Inhibition of the CYP isoform-specific Activity by Sesamin.
As sesamin is a substrate of most of CYP isoforms examined in this study (Table 1) , it seems likely that a competitive inhibition is observed in drug metabolizing activities of those CYP isoforms. The effect of sesamin on CYP3A4 was also examined, because CYP3A4 metabolizes a large number of medicines, and is the most essential CYP isoform in drug metabolism. It is noted that most of severe drug-drug and drug-food factor interactions are related to CYP3A4. Thus, inhibitory effects of sesamin on each of CYP2C9-, 1A2-, and 3A4-dependent activities were examined in this study. As expected, competitive inhibition by sesamin was observed in these CYPs-dependent activities. The apparent K i values of sesamin were estimated to be 24, 75, and 4.2 μM, respectively. Thus, it was found that sesamin was a potent inhibitor of CYP3A4.
Mecanism-based inhibition of CYPs.
To examine MBI by sesamin, first we used the microsomal fraction of the recombinant yeast expressing each of CYP2C9, CYP1A2, and CYP3A4. Although , respectively, for CYP2C9-specific dicrofenac 4'-hydroxylation in human liver microsomes (Table 3) .
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Discussion
To our best knowledge, this is the first report to identify the human CYP isoforms responsible for sesamin metabolism, although some previous studies have demonstrated that sesamin appears to be catecholized by some kinds of CYPs (Nakai et al., 2003; Penalvo et al., 2005; Liu et al., 2006) . First, we used the recombinant yeast expression system, which had been used as a tool for prediction of drug metabolism in human body (Imaoka et al., 1996; Hayashi et al., 2000; Sakaki and Inouye, 2000; Inouye et al., 2002) , to identify the human CYP isoforms responsible for sesamin metabolism. Surprisingly, most of human CYPs examined in this study showed sesamin catecholization (Table 1 ).
In particular, four kinds of CYPs (CYP1A2, 2C9, 2C19, and 2D6) had high ability to catecholize sesamin, compared with other CYPs. The kinetic studies suggested that CYP2C19 had the highest turnover for sesamin catecholization among human CYPs (Table 2) . However, based on their average contents in human liver, we predicted that the contribution in human liver is large in order of CYP2C9, 1A2, 2C19, and 2D6.
To examine our assumption, we performed experiments using individual human single donor liver microsomes (Figs.2 and 3) and a 50 donor human liver microsome pool (Fig.4) . The experimental data strongly suggested that CYP2C9 was largely responsible for sesamin catecholization in human liver, whereas CYP1A2 also made a small contribution. A significant inhibitory effect of the CYP2C9-specific inhibitor, sulfaphenazole, on sesamin catecholization in the pooled human liver microsomes confirmed that CYP2C9 was the most essential CYP isoform. However, the fact that inter-individual difference in sesamin catecholization activity (activity range: 2.5-fold)
was smaller than that of diclofenac 4'-hydroxylation activity (activity range: 6.3-fold) might be related with the contribution of CYP1A2. Contribution of CYP2C19 for sesamin catecholization in human liver appears to be small, though CYP2C19 has the D M D # 3 5 6 5 9 1 8 largest turnover (Table 1) . No significant inhibitory effect of the CYP2C19-specific inhibitor, (+)-N-3-benzylnirvanol, on sesamin catecholization in the pooled human liver microsomes confirmed that the contribution CYP2C19 is small. The contribution of CYP2D6 is also quite small, although some kind of methylenediphenyl compounds such as methylenedioxymethamphetamine (MDMA) is metabolized to catechol metabolites mainly by CYP2D6 (Tucker et al., 1994; Lin et al., 1997; Kreth et al., 2000) .
Both of CYP2C19 and CYP2D6 are known to have genetic polymorphisms. The frequency of CYP2C19 poor metabolizer (PM) in Japan and Korea is approximately 20 % and that of CYP2D6 PM in Caucasian is approximately 7~10 %. Thus, our conclusion that CYP2C19 and CYP2D6 are not essential for sesamin catecholization may predict a small inter-individual difference in sesamin metabolism.
One of the most important findings in this study is that sesamin is a mechanismbased inhibitor of CYP2C9. Figure 6 shows a putative reaction mechanism of sesamin catecholization proposed by Murray (2000) . A part of the metabolite (I) produced by CYP2C9 could be converted spontaneously to form a reactive carbene compound (II) which probably covalently binds to a heme iron of CYP2C9. As MBI inactivates the enzyme irreversiblely, it is a remarkably severe inhibition as compared with a reversible competitive inhibition. The K i and k inact values of sesamin were estimated to be 22 μM, (Zhou et al., 2004) . Judging from k inact /K i value, sesamin is a weak inhibitor as compared with these inhibitors (Table 3) . However, CYP2C9 is a major CYP isoform to metabolize therapeutic drugs such as diclofenac, phenytoin, and
S-warfarin. These results suggest that a drug-sesamin interaction should be evaluated on these therapeutic drugs. On the other hand, sesamin did not irreversibly inhibit CYP1A2
which is the secondary most important CYP isoform for sesamin catecholization.
Conversion from (I) to (II) or (III) is a spontaneous reaction (Fig. 6 ). Thus, it is possible that the reactive metabolite (II) is also produced in the substrate-binding pocket of CYP1A2, but the metabolite (II) may not rapidly attack a heme iron of CYP1A2.
Otherwise, MI-complex with CYP1A2 might be much less stable than that with In this study, we examined the metabolism of sesamin and revealed CYP isoforms involved in sesamin metabolism by combination of the yeast expression system for human CYPs and human liver microsomes. In particular, whole cell system of the recombinant yeast cells is useful for screening of CYP isoforms involved in the metabolism, and production of the metabolite to identify its chemical structure. We found that CYP2C9 was the most important CYP isoform in sesamin catecholization in human liver, but also found that sesamin was a mechanism-based inhibitor of CYP2C9.
At the present time, it is difficult to regard the MBI of CYP2C9 by sesamin as a serious problem, because no severe drug-sesamin interaction has been reported to our best knowledge. Pelnavo et al. (2005) reported that the peak plasma concentration of sesamin was only 0.1 μM after a single serving of sesame seeds containing 170mg of sesamin. Thus, much lower concentration of sesamin in vivo than the apparent inhibitor constant (K i app ) shown in Table 3 This article has not been copyedited and formatted. The final version may differ from this version. 
